Back

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Hypertension e-posters Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Associate Professor Wei Song

First Affiliated Hospital of Dalian Medical University, Dalian (China)

110 More presentations in this session

Presentation thumbnail
Exercise intensities modulate cognitive function in spontaneously hypertensive rats through oxidative mediated synaptic plasticity in hippocampus
Professor T. Lee (Tainan, TW)
Abstract Slides
Presentation thumbnail
Arterial stiffness and the risk of heart failure formation in rotational shift workers in the arctic
Doctor N. Shurkevich (Tyumen, RU)
Abstract Slides
Presentation thumbnail
Marital status, cardiovascular events, and intensive blood pressure lowering among men and women in the Systolic Blood Pressure Intervention Trial
Doctor M. Pareek (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Greater event rates in high-risk patients with a history of heart disease: from the Systolic Blood Pressure Intervention Trial (SPRINT)
Doctor M. Pareek (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Renal denervation in truly resistant hypertensive patients: six-year follow-up results of a single-center study
Doctor M. Ionov (Saint Petersburg, RU)
Abstract Slides

Access the full session

Session thumbnail
Hypertension e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac
21 May 2023
thumbnail
Congress Presentation
Understanding the management of hypertension in Asia: results of a literature search
2 December 2022
thumbnail
Congress Presentation
Reaming at resistant hypertension: old weapons brought back.
25 April 2024
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources